Bank Of New York Mellon Corp Spruce Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.99 - $1.43 $91,156 - $131,670	92,077 New	92,077 $101,000
Q2 2022 Aug 15, 2022	SELL	$1.28 - $2.23 $30,383 - $52,933	-23,737 Reduced 20.37%	92,764 $161,000
Q1 2022 May 11, 2022	BUY	$1.85 - $4.59 $163,924 - $406,710	88,608 Added 317.67%	116,501 $234,000
Q4 2021 Feb 11, 2022	BUY	$2.33 - $5.74 $1,036 - $2,554	445 Added 1.62%	27,893 $124,000
Q3 2021 Nov 12, 2021	BUY	$6.01 - $11.26 $11,310 - $21,191	1,882 Added 7.36%	27,448 $165,000
Q2 2021 Aug 11, 2021	BUY	$10.12 - $17.46 $64,626 - $111,499	6,386 Added 33.3%	25,566 $286,000
Q1 2021 May 13, 2021	BUY	$14.8 - $25.79 $84,182 - $146,693	5,688 Added 42.16%	19,180 $318,000
Q4 2020 Feb 09, 2021	BUY	$15.38 - $32.42 $207,506 - $437,410	13,492 New	13,492 $327,000

6.95M

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $216M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.